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Description
A 29-year-old previously healthy man presented to 
the hospital with a 2-month history of generalised 
weakness and swelling of the right eyelid. Phys-
ical examination showed ptosis of the right eye 
(figure 1A). In addition, he was anaemic and had 
had a decreased breath sound on the left lung. White 
cell count was 78 000 cells/mm3, haemoglobin was 
5.3 g/dL and platelet was 63 000 cells/mm3. Periph-
eral blood smear revealed immature circulating cells 
(figure 1B). Flow cytometry was positive for CD34, 
CD117 and CD13, compatible with acute myeloid 
leukaemia (AML). Whole body CAT scan demon-
strated infiltrative orbital mass at right eyelid and 
the superior aspect of right orbit (figure 1C,D) and a 
pleural-based left lower lung mass with associated left 
pleural effusion. Cytology of pleural fluid was positive 
for numerous blast cells. Biopsy of retro-orbital mass 
was deferred due to the concern of bleeding compli-
cation. He was immediately started on an induction 
chemotherapy regimen consisting of idarubicin and 
cytarabine. Circulating blasts rapidly declined and, 
correspondingly, eyelid swelling and pleural effusion 
were diminished.
Myeloid sarcoma (MS), also called extramed-
ullary disease of AML, or chloroma, is a rare 
disease, occurring in only 2%–8% of patients with 
AML. It can present as an isolated extramedullary 
leukaemic tumour, concurrently with AML, or 
at relapse. Pathobiology of MS could be related 
to an aberrant homing signal for the leukaemic 
blasts allowing for clonal expansion outside of 
the more common bone marrow localisation. MS 
is most commonly reported in the skin, bone and 
lymph nodes. Owing to the rarity of MS, prog-
nostic factors in these patients remain unknown. 
While it has been correlated with poor prognosis 
in adult, the superior outcome has been observed 
in paediatric AML with orbital and central nervous 
system MS.1 Currently, recommended treatment 
is systemic therapy with induction regimen used 
in AML (combination of cytarabine and anthracy-
clines) in patients presenting with isolated MS or 
MS presenting concomitantly with AML, because 
of high failure rate associated with local treatment 
alone (88%–100% vs 42%).2 Radiotherapy does 
not prolong overall survival but is commonly used 
to palliate symptoms. Orbital granulocytic sarcoma 
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Figure 1 (A) A photograph at presentation demonstrating right eyelid swelling with ptosis. (B) Peripheral blood 
smear showing multiple blast cells. Axial (C) and sagittal (D) CT images demonstrating a right orbital mass.
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occurs more commonly in paediatric rather than adult AML. 
Rapid visual loss from orbitopathy leading to compression of the 
optic nerve is an oncological emergency.3 Decompressive surgery 
and radiation have both been used successfully.
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Learning points
 ► Myeloid sarcoma, a rare presentation of acute myeloid 
leukaemia (AML), can occur as an isolated extramedullary 
leukaemic tumour, concurrently with, or at relapse.
 ► Recommended treatment is systemic therapy with induction 
regimen used in AML (combination of cytarabine and 
anthracyclines).
 ► Orbital granulocytic sarcoma can progress rapidly resulting in 
permanent visual loss and is an oncological emergency that 
may require decompressive surgery or radiation.
